Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increased NKCC1 expression in refractory human epilepsy.

Arjune Sen1, Lillian Martinian, Margareta Nikolic

  • 1Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, United Kingdom.

Epilepsy Research
|March 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NMDAR-antibody encephalitis: Seizure semiology and EEG findings.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Towards a Unified Research Agenda: International Consensus to Advance Understanding and Prevention of Sudden Unexpected Death in Epilepsy.

Epilepsy currents·2026
Same author

The prevalence and determinants of epilepsy in Ghana: A population-based study in two districts using a three-stage approach.

Epilepsia·2026
Same author

Postmortem MRI reveals distinct structural features in sudden unexpected death in epilepsy.

Epilepsia open·2026
Same author

Accuracy of epilepsy screening tools in community and primary care settings across countries in Sub-Saharan Africa: systematic review and meta-analysis protocol.

BMJ open·2026
Same author

The Relationship Between Sleep, Cognition, and Dementia Risk in People With Focal Epilepsy.

Neurology·2026
Same journal

Comment on "Predictors of surgical outcome in frontal lobe epilepsy: Experience from a single-center cohort in Latin America".

Epilepsy research·2026
Same journal

Response to: "A critical appraisal of principal component analysis of antiseizure medication-induced hostility/aggression and factor analysis of levetiracetam".

Epilepsy research·2026
Same journal

Access to inpatient video-EEG monitoring for patients with frequent seizure-related emergency visits.

Epilepsy research·2026
Same journal

Effect of the ketogenic diet on absence seizures in rats with genetic absence epilepsy.

Epilepsy research·2026
Same journal

Diagnostic accuracy of artificial intelligence models for seizure outcome prediction after epilepsy surgery: A systematic review and meta-analysis.

Epilepsy research·2026
Same journal

Quality assessment of persian epilepsy mobile applications: A systematic review using uMARS and DISCERN.

Epilepsy research·2026
See all related articles

Cation-chloride co-transporters (CCTs), specifically NKCC1, are implicated in epilepsy. This study found increased NKCC1 in hippocampal sclerosis and focal cortical dysplasia, suggesting it as a potential therapeutic target for drug-resistant epilepsy.

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Cation-chloride co-transporters (CCTs) play a role in neuronal function.
  • NKCC1, a specific CCT, is increasingly recognized for its potential involvement in epileptogenesis.
  • Pharmacoresistant epilepsy often involves underlying pathologies like hippocampal sclerosis (HS) and focal cortical dysplasia (FCD).

Purpose of the Study:

  • To investigate the expression and distribution of NKCC1 in HS and FCD.
  • To determine if NKCC1 levels differ between diseased and histologically normal brain tissue.
  • To evaluate NKCC1 as a potential therapeutic target for pharmacoresistant epilepsy.

Main Methods:

  • Histological examination of brain tissue samples from patients with HS and FCD.

Related Experiment Videos

  • Immunohistochemical analysis to detect and quantify NKCC1 immunoreactivity.
  • Comparison of NKCC1 levels in affected tissue versus adjacent normal-appearing cortex.

    • Main Results:

    • Consistently increased NKCC1 immunoreactivity was observed in both HS and FCD tissues.
    • No significant increase in NKCC1 immunoreactivity was found in adjacent histologically normal cortex.
    • These findings highlight a specific pathological change associated with these epilepsy-related lesions.

    Conclusions:

    • NKCC1 upregulation in HS and FCD suggests its involvement in the pathogenesis or pathophysiology of these conditions.
    • The observed increase in NKCC1 may contribute to the hyperexcitability seen in pharmacoresistant epilepsy.
    • Targeting NKCC1 presents a potential novel therapeutic strategy for treating drug-resistant epilepsy associated with HS and FCD.